A number of other analysts have also weighed in on the company. Guggenheim assumed coverage on Rubius Therapeutics in a research note on Thursday, May 30th. They issued a “buy” rating and a $25.00 target price for the company. Zacks Investment Research upgraded Rubius Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 24th. Finally, HC Wainwright initiated coverage on Rubius Therapeutics in a research note on Wednesday, June 26th. They issued a “buy” rating and a $40.00 target price for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Rubius Therapeutics currently has an average rating of “Buy” and an average target price of $31.00.
Shares of NASDAQ RUBY traded down $0.93 during midday trading on Thursday, reaching $11.97. 260,242 shares of the company traded hands, compared to its average volume of 150,004. The business’s 50-day moving average price is $14.57. Rubius Therapeutics has a 12 month low of $11.61 and a 12 month high of $26.90. The company has a debt-to-equity ratio of 0.13, a quick ratio of 18.64 and a current ratio of 18.64.
In other news, insider Christopher L. Carpenter sold 47,757 shares of the business’s stock in a transaction dated Wednesday, June 19th. The stock was sold at an average price of $14.02, for a total transaction of $669,553.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Langer sold 7,500 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $14.94, for a total value of $112,050.00. The disclosure for this sale can be found here. 58.40% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of RUBY. BlackRock Inc. grew its position in shares of Rubius Therapeutics by 52.9% during the 4th quarter. BlackRock Inc. now owns 2,430,505 shares of the company’s stock worth $39,083,000 after buying an additional 840,707 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Rubius Therapeutics during the 1st quarter worth about $14,995,000. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Rubius Therapeutics by 147.3% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,241,299 shares of the company’s stock worth $19,526,000 after buying an additional 739,449 shares during the period. Nikko Asset Management Americas Inc. grew its position in shares of Rubius Therapeutics by 142.3% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,254,158 shares of the company’s stock worth $19,728,000 after buying an additional 736,490 shares during the period. Finally, FMR LLC grew its position in shares of Rubius Therapeutics by 8.9% during the 1st quarter. FMR LLC now owns 7,019,730 shares of the company’s stock worth $127,057,000 after buying an additional 573,662 shares during the period. Institutional investors own 93.75% of the company’s stock.
Rubius Therapeutics Company Profile
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
Further Reading: Rule of 72
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.